We believe this transaction, particularly when leveraged with our SoftBank relationship, is further validation of our strategy and allows Sprint to control its network destiny.

ENGADGET: Sprint confirms it's buying the rest of Clearwire for $2.2 billion

It appears to be superior to standard antibody-based quality-control tests currently used for that purpose, but such scientific advances will need to undergo extensive validation studies before they can be considered a reliable predictor of effects in vivo and eliminate the need for clinical data.

FORBES: Do You Think 'Biosimilars' Will Reduce Healthcare Expenditures? Think again.